ARTICLE | Deals
BioCentury’s Deals Report also includes GSK’s agreement with Flagship-backed Vesalius in Parkinson’s disease, and more
By Paul Bonanos, Director of Biopharma Intelligence, and Gunjan Ohri, Data Content Analyst
November 19, 2024 1:28 AM UTC
Two Western biopharmas made headlines last week by entering deals with China-based biotechs around an emerging class of bispecifics, and the drumbeat continued early this week with more deals for other bifunctional antibodies.
The bigger deals drawing attention were around anti-PD-(L)1 x VEGF bispecifics, as BioNTech SE (NASDAQ:BNTX) acquired Biotheus Inc. for $800 million up front, and Merck & Co. Inc. (NYSE:MRK) took global rights to a program from LaNova Medicines Ltd. for $588 million…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654230/more-bispecific-deals-in-china-aclaris-biosion-ouro-keymed-avenzo-velavigo